Answers are grounded in this paper and cite their sources.
Despite steady advances in synthetic methodology, the reactions routinely used in medicinal chemistry have changed little over several decades, which suggests that discovering a reaction and establishing it as a practical tool are separate challenges. Academic methods are typically judged by yield, selectivity, and scope, whereas industrial adoption also depends on supply-chain security, reagent availability, and scalability. As a supplier of building blocks for drug discovery, we at Enamine examined this gap through a collaboration with the Schindler laboratory, aimed at translating the group’s 2019 visiblelight-mediated intramolecular aza Paternò–Büchi reaction into a commercial azetidine building block pipeline. Using an inexpensive organic photosensitizer, we successfully scaled the key [2+2] photocycloaddition in batch and flow, delivering 12 unique azetidine building blocks on up to 50 g scale, and accessed five additional scaffolds through post-synthetic modification. The remaining barriers arose outside the key step and traced to the oxime auxiliary that the cycloaddition requires, which limited both substrate preparation and access to free N–H azetidines. The findings from this case study show that translational readiness depends on the full synthetic sequence, and a stage-by-stage assessment identifies where further development is needed before industry uptake can be successful.
No takes yet. Share an insight, caveat, or question.
Shpotia et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: